Answer
Cemiplimab (Libtayo) is indicated as monotherapy for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Sources for this answer
- LIBTAYO 350 mg concentrate for solution for infusion.Regeneron UK Limited · emc · SmPC §4.1 Therapeutic Indications · Version 24Document updated
Sources checked